NEW YORK – Swedish startup Moleculent said Tuesday that it has raised $26 million in Series A financing.
Arch Venture Partners led the round, joined by Eir Ventures and existing investors. Arch Venture Partners has also invested in spatial biology firm Vizgen. Arch's Patrick Weiss has been appointed chairman, joined on the board by Sean Kendall and Eir's Magnus Persson.
Moleculent, based in Solna, Sweden, said it will use the funds to advance its technology to detect cell-cell interactions and profile cell communication directly in the tissue environment. The company will analyze functional proteins, including receptors and ligands, but declined to provide additional details about its technology.
"The Moleculent platform has been designed to allow scientists to uncover radical new insights into the cellular level of human biology and pathology," Moleculent CEO and Cofounder Olle Ericsson said in a statement. "Understanding cell-cell communication networks in clinical samples has the potential to bring us into a new era of understanding functional biology and human disorders."